Clinical trial
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
NCT02073487
Study timeline
Study start (unknown)2014-02-01Date precision: month
Registry last updated2021-09-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
T-DM1DRUG
TrastuzumabDRUG · verified · RxNorm: trastuzumab
LapatinibDRUG · verified · RxNorm: lapatinib
AbraxaneDRUG · verified · RxNorm: Abraxane
PaclitaxelDRUG · verified · RxNorm: paclitaxel
PertuzumabDRUG · verified · RxNorm: pertuzumab
Sponsors & collaborators
The Methodist Hospital Research Institutelead sponsor
Celgene Corporationcollaborator
Novartiscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02073487 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.